Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology reported in abstract
PubMed 34855694 · doi:10.1097/YCO.0000000000000759
What was done
This narrative review synthesized current clinical and preclinical evidence on psychedelic-assisted therapies (including psilocybin, DMT/ayahuasca, LSD, and MDMA) for psychiatric and mood disorders, as well as the evidence surrounding microdosing.
What was found
The abstract reports qualitative trial findings without quantitative effect sizes or statistics. Randomized placebo-controlled trials show psilocybin combined with psychological support is effective for depression and treatment-resistant depression. DMT/ayahuasca shows emergent potential for depression, LSD demonstrates anxiolytic effects, and MDMA has Phase III trial support for treating post-traumatic stress disorder. Conversely, a self-directed controlled trial found no evidence that microdosing improved mood.
Why it matters
It provides an overview of the clinical landscape for psychedelic pharmacotherapies, highlighting their therapeutic potential as psychotherapeutic adjuncts alongside key pharmacological and mechanistic considerations.
Limits
As a narrative review, it lacks systematic search criteria, meta-analytic pooling, or formal risk-of-bias grading. The underlying literature is characterized by small sample sizes, substantial blinding challenges due to psychoactive effects, and a lack of definitive Phase III trials for mood disorder indications.